Microvascular Experimentation in the Chick Chorioallantoic Membrane As a Model for Screening Angiogenic Agents Including from Gene-Modified Cells

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Jan 11

PMID 35008876

Authors

Donna C Kennedy

Barbara Coen

Antony M Wheatley

Karl J A McCullagh

Affiliations

Soon will be listed here.

Abstract

The chick chorioallantoic membrane (CAM) assay model of angiogenesis has been highlighted as a relatively quick, low cost and effective model for the study of pro-angiogenic and anti-angiogenic factors. The chick CAM is a highly vascularised extraembryonic membrane which functions for gas exchange, nutrient exchange and waste removal for the growing chick embryo. It is beneficial as it can function as a treatment screening tool, which bridges the gap between cell based in vitro studies and in vivo animal experimentation. In this review, we explore the benefits and drawbacks of the CAM assay to study microcirculation, by the investigation of each distinct stage of the CAM assay procedure, including cultivation techniques, treatment applications and methods of determining an angiogenic response using this assay. We detail the angiogenic effect of treatments, including drugs, metabolites, genes and cells used in conjunction with the CAM assay, while also highlighting the testing of genetically modified cells. We also present a detailed exploration of the advantages and limitations of different CAM analysis techniques, including visual assessment, histological and molecular analysis along with vascular casting methods and live blood flow observations.

Citing Articles

Standardization to Characterize the Complexity of Vessel Network Using the Aortic Ring Model.

Wolint P, Hofmann S, von Atzigen J, Boni R, Miescher I, Giovanoli P Int J Mol Sci. 2025; 26(1.

PMID: 39796147 PMC: 11719671. DOI: 10.3390/ijms26010291.

Development of Solid Nanosystem for Delivery of Chlorhexidine with Increased Antimicrobial Activity and Decreased Cytotoxicity: Characterization and In Vitro and In Ovo Toxicological Screening.

Danila A, Rominu M, Munteanu K, Moaca E, Geamantan-Sirbu A, Olariu I Molecules. 2025; 30(1.

PMID: 39795218 PMC: 11721946. DOI: 10.3390/molecules30010162.

The Chicken Embryo: An Old but Promising Model for In Vivo Preclinical Research.

Sarnella A, Ferrara Y, Terlizzi C, Albanese S, Monti S, Licenziato L Biomedicines. 2025; 12(12.

PMID: 39767740 PMC: 11673736. DOI: 10.3390/biomedicines12122835.

Anti-angiogenic Potential of Trans-chalcone in an Chick Chorioallantoic Membrane Model: An ATP Antagonist to VEGFR with Predicted Blood-brain Barrier Permeability.

Senrung A, Tripathi T, Aggarwal N, Janjua D, Chhokar A, Yadav J Cardiovasc Hematol Agents Med Chem. 2023; 22(2):187-211.

PMID: 37936455 DOI: 10.2174/0118715257250417231019102501.

Cutaneous Polymeric-Micelles-Based Hydrogel Containing L. Essential Oil: In Vitro Release and Permeation, Angiogenesis, and Safety Profile In Ovo.

Avram S, Bora L, Vlaia L, Mut A, Olteanu G, Olariu I Pharmaceuticals (Basel). 2023; 16(7).

PMID: 37513852 PMC: 10383657. DOI: 10.3390/ph16070940.

References

Yang E, Moses H . Transforming growth factor beta 1-induced changes in cell migration, proliferation, and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol. 1990; 111(2):731-41. PMC: 2116177. DOI: 10.1083/jcb.111.2.731. View

Mira E, Lacalle R, Gomez-Mouton C, Leonardo E, Manes S . Quantitative determination of tumor cell intravasation in a real-time polymerase chain reaction-based assay. Clin Exp Metastasis. 2002; 19(4):313-8. DOI: 10.1023/a:1015563031769. View

Kue C, Tan K, Lam M, Lee H . Chick embryo chorioallantoic membrane (CAM): an alternative predictive model in acute toxicological studies for anti-cancer drugs. Exp Anim. 2015; 64(2):129-38. PMC: 4427727. DOI: 10.1538/expanim.14-0059. View

Paterson T, Gigliobianco G, Sherborne C, Green N, Dugan J, MacNeil S . Porous microspheres support mesenchymal progenitor cell ingrowth and stimulate angiogenesis. APL Bioeng. 2019; 2(2):026103. PMC: 6481713. DOI: 10.1063/1.5008556. View

He R, Li X, Liang L, Xie Y, Luo D, Ma J . The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model. BMC Cancer. 2017; 17(1):655. PMC: 5606087. DOI: 10.1186/s12885-017-3646-1. View

Dikici S, Mangir N, Claeyssens F, Yar M, MacNeil S . Exploration of 2-deoxy-D-ribose and 17β-Estradiol as alternatives to exogenous VEGF to promote angiogenesis in tissue-engineered constructs. Regen Med. 2019; 14(3):179-197. DOI: 10.2217/rme-2018-0068. View

Nkembo A, Ntantie E, Salako O, Amissah F, Poku R, Latinwo L . The antiangiogenic effects of polyisoprenylated cysteinyl amide inhibitors in HUVEC, chick embryo and zebrafish is dependent on the polyisoprenyl moiety. Oncotarget. 2016; 7(42):68194-68205. PMC: 5356549. DOI: 10.18632/oncotarget.11908. View

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

Volpert O, Tolsma S, Pellerin S, Feige J, Chen H, Mosher D . Inhibition of angiogenesis by thrombospondin-2. Biochem Biophys Res Commun. 1995; 217(1):326-32. DOI: 10.1006/bbrc.1995.2780. View

10.

Zacchigna S, Zentilin L, Morini M, Delleva R, Noonan D, Albini A . AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Ther. 2003; 11(1):73-80. DOI: 10.1038/sj.cgt.7700657. View

11.

Heuberger D, Harankhedkar S, Morgan T, Wolint P, Calcagni M, Lai B . High-affinity Cu(I) chelator PSP-2 as potential anti-angiogenic agent. Sci Rep. 2019; 9(1):14055. PMC: 6773859. DOI: 10.1038/s41598-019-50494-5. View

12.

Steinle H, Golombek S, Behring A, Schlensak C, Wendel H, Avci-Adali M . Improving the Angiogenic Potential of EPCs via Engineering with Synthetic Modified mRNAs. Mol Ther Nucleic Acids. 2018; 13:387-398. PMC: 6198099. DOI: 10.1016/j.omtn.2018.09.005. View

13.

Barnhill R, Ryan T . Biochemical modulation of angiogenesis in the chorioallantoic membrane of the chick embryo. J Invest Dermatol. 1983; 81(6):485-8. DOI: 10.1111/1523-1747.ep12522728. View

14.

Yang M, Hung C, Chang C, Tseng T, Wang C . Solanum nigrum Suppress Angiogenesis-Mediated Tumor Growth Through Inhibition of the AKT/mTOR Pathway. Am J Chin Med. 2016; 44(6):1273-1288. DOI: 10.1142/S0192415X16500713. View

15.

Vazquez F, Hastings G, Ortega M, Lane T, Oikemus S, Lombardo M . METH-1, a human ortholog of ADAMTS-1, and METH-2 are members of a new family of proteins with angio-inhibitory activity. J Biol Chem. 1999; 274(33):23349-57. DOI: 10.1074/jbc.274.33.23349. View

16.

Deryugina E, Zijlstra A, Partridge J, Kupriyanova T, Madsen M, Papagiannakopoulos T . Unexpected effect of matrix metalloproteinase down-regulation on vascular intravasation and metastasis of human fibrosarcoma cells selected in vivo for high rates of dissemination. Cancer Res. 2005; 65(23):10959-69. DOI: 10.1158/0008-5472.CAN-05-2228. View

17.

Wartenberg M, Gunther J, Hescheler J, Sauer H . The embryoid body as a novel in vitro assay system for antiangiogenic agents. Lab Invest. 1998; 78(10):1301-14. View

18.

Zijlstra A, Mellor R, Panzarella G, Aimes R, Hooper J, Marchenko N . A quantitative analysis of rate-limiting steps in the metastatic cascade using human-specific real-time polymerase chain reaction. Cancer Res. 2002; 62(23):7083-92. View

19.

Hagenbuchner J, Rupp M, Salvador C, Meister B, Kiechl-Kohlendorfer U, Muller T . Nuclear FOXO3 predicts adverse clinical outcome and promotes tumor angiogenesis in neuroblastoma. Oncotarget. 2016; 7(47):77591-77606. PMC: 5363607. DOI: 10.18632/oncotarget.12728. View

20.

Babae N, Bourajjaj M, Liu Y, van Beijnum J, Cerisoli F, Scaria P . Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma. Oncotarget. 2014; 5(16):6687-700. PMC: 4196156. DOI: 10.18632/oncotarget.2235. View